Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized Study
Open Access
- 1 September 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 170 (3), 777-782
- https://doi.org/10.1097/01.ju.0000080568.91703.18
Abstract
PURPOSE: In laboratory studies electromotive mitomycin C (MMC) demonstrated markedly increased transport rates compared with passive transport. We performed a prospective study in patients with high risk superficial bladder cancer to assess the efficacy of intravesical electromotive vs passive MMC using bacillus Calmette-Guerin (BCG) as a comparative treatment.ud ud MATERIALS AND METHODS: Following transurethral resection and multiple biopsies 108 patients with multifocal Tis, including 98 with T1 tumors, were randomized into 3 equal groups of 36 each who underwent 40 mg electromotive MMC instillation with 20 mA electric current for 30 minutes, 40 mg passive MMC with a dwell time of 60 minutes or 81 mg BCG with a dwell time of 120 minutes. Patients were scheduled for an initial 6 weekly treatments, a further 6 weekly treatments for nonresponders and a followup 10 monthly treatments for responders. Primary end points were the complete response rate at 3 and 6 months. MMC pharmacokinetics were assessed.ud ud RESULTS: The complete response for electromotive vs passive MMC at 3 and 6 months was 53% versus 28% (p = 0.036) and 58% versus 31% (p = 0.012). For BCG the responses were 56% and 64%. Median time to recurrence was 35 vs 19.5 months (p = 0.013) and for BCG it was 26 months. Peak plasma MMC was significantly higher following electromotive MMC than after MMC (43 vs 8 ng/ml), consistent with bladder content absorption.ud ud CONCLUSIONS: Intravesical electromotive administration increases bladder uptake of MMC, resulting in an improved response rate in cases of high risk superficial bladder cancerKeywords
This publication has 12 references indexed in Scilit:
- Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III TrialJNCI Journal of the National Cancer Institute, 2001
- THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, 2001
- THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORSJournal of Urology, 1999
- The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year OutcomeJournal of Urology, 1997
- Iontophoresis of Drugs in the Bladder Wall: Equipment and Preliminary StudiesArtificial Organs, 1993
- Natural history of early bladder cancerJournal of Cellular Biochemistry, 1992
- Editorial CommentsJournal of Urology, 1990
- Iontophoretic Delivery Model Inorganic and Drug IonsJournal of Pharmaceutical Sciences, 1989
- Stage T1, Grade 3 Transitional Cell Carcinoma of the Bladder: An Unfavorable Tumor?Journal of Urology, 1987
- Peritoneal ultrafiltration dialysis: enhanced urea transfer using hypertonic peritoneal dialysis fluid.JCI Insight, 1966